RemeGen Biosciences

The company's business model is centered on its fully integrated, in-house platforms for drug discovery, development, manufacturing, and commercialization. It generates revenue through the sale of its approved drugs and through strategic licensing agreements. A significant milestone was the exclusive worldwide licensing and co-development agreement with Seagen (now part of Pfizer) for its HER2-targeted ADC, Disitamab Vedotin, in a deal valued at up to $2.6 billion. More recently, in June 2025, RemeGen granted exclusive rights outside of Greater China to Vor Bio for its autoimmune drug, Telitacicept, in a deal potentially worth over $4 billion, including an upfront payment, warrants, and future milestone payments.

RemeGen targets therapeutic areas with significant unmet medical needs, including autoimmune diseases, oncology, and ophthalmology. Its product pipeline includes several key assets. Telitacicept (RC18), a dual-target fusion protein, is approved in China for conditions like systemic lupus erythematosus (SLE) and myasthenia gravis. Disitamab Vedotin (RC48), an antibody-drug conjugate, is the first ADC developed in China to receive breakthrough therapy designations from both the U.S. FDA and China's NMPA, with approvals for gastric and urothelial cancers in China. The company has a robust pipeline with over 10 molecules in various stages of clinical development, utilizing its proprietary antibody, ADC, and bifunctional antibody (HiBody) platforms.